Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - prodotti oħrajn għal pressjoni għolja - trattament ta 'pressjoni għolja arterjali pulmonari (pah) biex tittejjeb il-kapaċità ta' eżerċizzju u s-sintomi f'pazjenti bl-organizzazzjoni dinjija tas-saħħa (who) klassi funzjonali iii. l-effikaċja ntweriet fi:primarja (idjopatika u familjali) u pah;pah sekondarja għal skleroderma mingħajr mard pulmonari interstizjali sinifikanti;pah marbuta ma'shunts sistemiċi-pulmonari konġenitali u eisenmenger tal-fiżjoloġija. xi titjib intwera wkoll f'pazjenti b'pah klassi funzjonali who ii. stayveer huwa ndikat ukoll biex inaqqas in-numru ta 'ulċeri ġodda fis-swaba f'pazjenti bi sklerosi sistemika u l-għaddejjin diġitali 'mard ta' ulċera.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - għal pressjoni għolja, - kura ta 'pressjoni għolja arterjali pulmonari (pah) biex tittejjeb il-kapaċità ta' eżerċizzju u s-sintomi f'pazjenti bi klassi funzjonali tal-who iii. efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. xi titjib intwera wkoll f'pazjenti b'pah klassi funzjonali who ii. tracleer huwa ndikat ukoll biex inaqqas in-numru ta ' ulċeri ġodda fis-swaba f'pazjenti bi sklerosi sistemika u l-ulċeri kontinwu tal-mard.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunosoppressanti - crohn diseasestelara huwa indikat għall-kura ta 'pazjenti adulti b'attiva minn moderata sa gravi marda ta' crohn li kellhom rispons inadegwat b', tilfu r-rispons għal, jew li kienu intolleranti jew terapija konvenzjonali jew tnfa antagonista jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn. kolite colitisstelara huwa indikat għall-kura ta ' pazjenti adulti b'attiva minn moderata sa gravi kolite bl-ulċeri li kellhom rispons inadegwat b', tilfu r-rispons għal, jew li kienu intolleranti jew terapija konvenzjonali jew bijoloġika jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn. plakka psoriasisstelara huwa indikat għall-kura moderata għal severa ta ' psorjasi tal-plakka f'adulti li naqsu milli jirrispondu għal, jew li għandhom kontraindikazzjoni għal, jew li huma intolleranti għal terapiji sistemiċi oħrajn inkluż ciclosporin, methotrexate u psoralen ultraviolet-a. pedjatrika tal-plakka psoriasisstelara huwa indikat għall-kura moderata għal severa ta 'psorjasi tal-plakka fit-tfal u pazjenti adolexxenti mill-età ta' 6 snin u akbar, li huma kkontrollati b'mod inadegwat minn, jew li huma intolleranti għal, terapiji jew fototerapiji sistemiċi oħrajn. psorjatika arthritisstelara, waħdu jew f'taħlita ma 'methotrexate, huwa indikat għall-kura ta' artrite psorjatika attiva f'pazjenti adulti meta r-rispons għall-preċedenti mhux bijoloġika li jimmodifikaw il-marda anti-rewmatiċi tad-droga (dmard) it-terapija kienet inadegwata.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psorajiżi - immunosoppressanti - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine hydrochloride - mard depressiv - anti-depressanti oħrajn - spravato, f'kombinazzjoni ma 'ssri jew snri, huwa indikat għall-pazjenti adulti bil-kura reżistenti disturb dipressiv maġġuri, li ma wieġbux għal mill-inqas żewġ trattamenti differenti b'anti-depressivi fil-kurrenti moderata għal severa episodju ta' dipressjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - emorraġiku-deni, l-ebola - vaċċini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - emorraġiku-deni, l-ebola - vaċċini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - majloma multipla - aġenti antineoplastiċi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatika neoplażmi, il-kastrazzjoni-reżistenti - aġenti antineoplastiċi - treatment of adult patients with prostate cancer.